

Product & Services

**Based on an Innovative Platform
Technology
for Screening in Mammalian Cells**

CytoPathfinder

Our Potential Customers

We are providing our solid-phase transfection(STF) plates in cellular research for

- 1.facilitating target discovery and alternative pathway analysis
- 2.RNAi-based compound profiling for designing rational combination of drugs

Our potential customers would be Researchers
Who have problem such as



- we have no suitable method to transfect into our target cell

also who have expectation such as

- we want to convert actual viral method to non viral
- we want to conduct large scale high-throughput screening more efficiently by small number of staff
- we want to conduct gene editing research work in house instead of outsourcing.

CytoPathfinder

Our Products and services


- siRNA / miRNA / Plasmid DNA (supplied from clients)
 - Plates for sale for use in customer's laboratory
 - Transfection Optimization plates
 - Customized plates
 - Large scale screening plates

- **Non viral method of Gene Editing using CRISPR – Cas9 System**
(Cas9 and g-RNA are supplied from clients)

■ Types of solid-phase CRISPR / Cas9 plates
(including under development)


Cas9	gRNA	
	Plasmid	RNA
Cas9-introduced cells	Kits for plasmid	Kits for RNA
plasmid	Kits for plasmid	under development
mRNA	under development	under development

- **In vitro siRNA transfection assay kits for human hepatocyte cells from PXB mice**



CytoPathfinder

How to use our products for screening processes?

Steps	<div>Transfection condition screen</div> <div>Assay Development</div> <div>Screening</div>		
Objectives	<ul style="list-style-type: none"> •To find several Solid-phase transfection candidate conditions for target cells •To find appropriate culture condition for seeding (ie. Serum-free treatment, Seeding density, culture time, etc.) 		<div>Cutdown</div>
Products	<div>  </div>	<div> <p>Name : Transfection Optimization Kit</p> <p><u>Transfection Optimization plate contents:</u></p> <ul style="list-style-type: none"> •For Hs/Ms/Rn species •384 plate (standard : <i>Corning#3712</i>) •Freezer storage (at least 1 yr.) •ca.140 compositions/plate <ul style="list-style-type: none"> ✓Transfection reagents (types & conc.) ✓siRNA conc. ✓siRNA (Negative & CytoTox siRNA) ✓Accelerator conc. </div>	<div> <p>Name : Customized plate</p> <p><u>Customized points:</u></p> <ul style="list-style-type: none"> •Free layout •Can use various manufacture's siRNA/miRNA (Ambion, Dharmacon, Qiagen, etc.; negatively charged) •Can use various types of plate (6, 96, 384, 1536well, PDL/PLL-coated, etc.) •Variable number of replica plates •Freezer storage (at least 1 yr.) </div>
Nucleic acid resources	<div>CytoPathfinder will provide</div>		<div>Client will provide (Basically)</div>
Assays	<div> <p><u>Viability assays:</u></p> <ul style="list-style-type: none"> •Luminescence (recommended) (Promega CellTiter-Glo, PE ATPLite, etc.) •Fluorescence (Promega CellTiter-Blue, etc.) •Absorbance (MTT, WST assay) •Image-based assay (GE INCell analyzer, PE Opera, etc.) <p>*CytoPathfinder will provide the analysis software (Excel macro)</p> </div>		<div> <p><u>Various assays:</u></p> <ul style="list-style-type: none"> •qPCR •Western blot •Reporter assay •ELISA •Image-based assay ...etc. </div>

Innovative tools in vitro study compared to actual method

Materials



Processing



Try & error by
specialist



CytoPathfinder's TF plate



Easy and effective


Reducibility and
Reliability

Products
(Results)

Data set for drug discovery
research and medical research

CytoPathfinder

Automated system for STF plate manufacturing



CytoPathfinder

Advantage over conventional transfection method

- Enhanced solid-phase transfection efficiency with proprietary accelerators and accumulated know-how
- Simple to use methodology/simpler transfection process
- Varied formats possible
- Simple optimisation process
- Excellent reproducibility and reliability
- Reliable results with hard-to-transfect cells
- Fewer cells needed per assay
- Dual knockdown easily achievable




Time, cost saving for getting reliable data

CytoPathfinder

Advantage over conventional method

Simple Process- Time, Labor, Cost saving



CytoPathfinder

Time saving

Conventional methods: (multiple try & error experiments)

Low efficiency
High toxicity



High efficiency
Low toxicity

~6 months



STF:

Low efficiency
High toxicity



High efficiency
Low toxicity

~1 month

CytoPathfinder

Cost saving

Conventional methods

- Cell
- Gene
- Medium
- etc.

Downsizing by STF methods

~1/1000 volume

•Human resource


~1/10 resource

CytoPathfinder

Advantage over conventional method

Enhanced Transfection Efficiency


- Patented accelerator increases rate and extent of transfection
 - Stabilises transfection complexes
 - Enhances uptake of complexes by cells
 - More cells transfected, less variability
- Facilitates well-to-well reproducibility



← The accelerator provides visibly higher efficiency

Advantage over conventional method

Simple to Use Methodology



CytoPathfinder supply Plates with the siRNA, Plasmid DNA transfection reagent and accelerator dried on the bottom of the wells.

Plates are stable for at least 12 months.

Customers simply add cells, incubate and read their preferred endpoint.


CytoPathfinder

Advantage over conventional method


Varied Formats Possible

Wells facilitate high-throughput screening


- 96,384 ,1536 well plates as standard



1536 well plate



384 well plate



96 well plate

- 6 well plate
(under development)



CytoPathfinder

Advantage over conventional method

Simple Optimisation Process

- ◆ Optimisation plate with wide range of permutations used to select conditions prior to full screening
 - Major bottleneck in other siRNA transfection methods
- ◆ Efficiency and toxicity assessed using lethal and non-coding siRNAs

Variables: (materials)

Over one hundred and forty conditions can be tested on a single plate.

- ✓ Nucleic acid concentration
- ✓ TF reagents; type & concentration
- ✓ Buffers



- ◆ Once optimal conditions selected, experimental plates produced by CytoPathfinder using siRNA library chosen by the customer

CytoPathfinder

Advantage over conventional method

Excellent reproducibility and reliability

Plates




- Plate to plate correlation > 0.9
- Z' values > 0.8 readily achievable

Advantage over conventional method

Reliable results with hard-to-transfect Cells

- Use of the accelerator also increases transfection in hard-to-transfect cells
- Allows excellent transfection with maintained cell viability
 - For example, human bronchial/tracheal epithelial cells



① record of STF into Cell Line

type	name	tissue / disease	nucleic acid
adherent	HeLa	cervix / adenocarcinoma	siRNA, Plasmid, RNA aptamer
adherent	T-47D	mammary gland, breast / ductal carcinoma	siRNA
adherent	SK-BR-3	mammary gland, breast / adenocarcinoma	siRNA
adherent	MCF7	mammary gland, breast / adenocarcinoma	siRNA, Plasmid, RNA aptamer
adherent	MDA-MB-231	mammary gland, breast / adenocarcinoma	siRNA
adherent	MDA-MB-435S	mammary gland, breast / ductal carcinoma	siRNA
adherent	HEK-293	embryonic kidney	siRNA, Plasmid
adherent	HEK-293T	embryonic kidney	siRNA, Plasmid
adherent	Caco-2	colon / colorectal adenocarcinoma	siRNA
adherent	HCT116	colon / colorectal adenocarcinoma	siRNA
adherent	SW480	colon / colorectal adenocarcinoma	siRNA
adherent	HepG2	liver / hepatocellular carcinoma	siRNA, Plasmid
adherent	NT2 (NTERA-2)	testis / malignant pluripotent embryonal carcinoma	siRNA, Plasmid
adherent	NIH/3T3	embryo	siRNA, Plasmid, RNA aptamer
adherent	3T3-L1	embryo	siRNA, RNA aptamer
adherent	MDCK	kidney / normal	siRNA
adherent	Malme-3M	lung / malignant melanoma	siRNA
adherent	SK-MEL-28	skin / malignant melanoma	siRNA
adherent	SK-MEL-5	skin / malignant melanoma	siRNA
adherent	A-375	skin / malignant melanoma	siRNA
adherent	NCI-H460	lung / carcinoma, large cell lung cancer	siRNA
adherent	A549	lung / carcinoma	siRNA, RNA aptamer
mixed	SH-SY5Y	bone marrow / neuroblastoma	siRNA
mixed	PC-12	adrenal gland / pheochromocytoma	siRNA, Plasmid
suspension	Jurkat	peripheral blood / acute T cell leukemia	siRNA
suspension	K-562	bone marrow / chronic myelogenous leukemia	siRNA, Plasmid
adherent	Neuro2a	Mouse neuroblastoma	Plasmid
suspension	THP-1	Human Monocytes/ acute monocytic leukemia	siRNA

② record of STF into Normal / Primary Cell

Name	tissue / disease	nucleic acid
Mice Bearing Human Tumor Xenografts		siRNA
Rat Brain Cortex Neuronal Cells		siRNA
Primary Rat Astrocytes		siRNA
Primary Rat Neuronal Cells		siRNA
Primary Mouse Neuronal Cells		siRNA
PMEF		siRNA
HUVEC	Normal Human Umbilical Vein Endothelial Cells	siRNA, Plasmid
Human Retinal Microvascular Endothelial Cells		siRNA
Rat Retinal Ganglion Cells		siRNA
HMEC	Normal Human Mammary Epithelial Cells	siRNA
NHBE	Normal Human Bronchial/Tracheal Epithelial Cells	siRNA
UASMC	Normal Human Umbilical Artery Smooth Muscle Cells	siRNA
NHDF-Neo	Normal Human Neonatal skin fibroblast	siRNA, Plasmid
Primary Human Hepatocytes from PXB-Mice®		siRNA
Chronic Lymphocytic Leukemia		siRNA
Normal Human B1 Cells		siRNA
Human Peripheral Blood CD14+ Monocytes		siRNA
hMSC	Human Mesenchymal Stem Cells	siRNA, Plasmid
mNSC	Mouse Neuronal Stem Cells	siRNA


Advantage over conventional method

Fewer Cells per Assay

- High transfection efficiency permits dense formats:
 - ✓ 384 well plates 3,000 cells/well
 - ✓ 1536 well plates 500 cells/well
 - ✓ 3456 well plates 100-200 cells/well
- Allows broader gene analysis with scarce cells
 - ✓ Primary cells
 - ✓ Human tumour cells with low passage number

$Z' = 0.77$


Neg. siRNA Cytotoxic siRNA



Advantage over conventional method

Dual Knockdown Easily Achievable

- ◆ Western blot showing knockdown of Gene 1 and Gene 2 separately and together (plus non-targeting control RNA – NTC)
- ◆ Effectiveness retained in dual knockdown



Advantage over conventional method

Solid-phase transfection combined with cutting-edge technologies

Explore ncRNA functional screening

Explore 2D/3D functional screening

miRNA mimics library
with **GeneDesign, Inc.**

One-Step Solid-phase Transfection Plate & **Micro RNA Mimics Library**

Easy to Operate **Ready to Use**

Hela Cell viability with miRNAs

miRNA	Trial 1	Trial 2
Hsp2	180	180
miR-1	150	150
miR-7	120	120
miR-133a	100	100
miR-203	130	130
miR-125b-5p	140	140
miR-145-5p	160	160
miR-143-3p	170	170
miR-486-3p	180	180
miR-146a-5p	190	190
miR-410	100	100
miR-126-3p	120	120
miR-53b-5p	140	140

- Single Tube or Plate Supply
- miRBase ver.18 Human & Mouse
- Scale Up and Labeling

Just "seed" and watch!
Enjoy high efficient miRNA transfection today!

For miRNA mimics: GeneDesign, Inc.
7-7-20 Saitoasagi, Ibaraki, Osaka 567-0085 Japan
Info-e@genedesign.co.jp
Phone: +81-72-640-5180
<http://www.genedesign.co.jp/e/>

Contracted manufacture service

NanoCulture® Plate with siRNA
for high-throughput RNAi screening in 3D cell culture

RNAi × 3D cell culture
New platform for RNAi screening

CytoPathfinder
Solid-phase transfection technology

scivax
NanoCulture® Plate

Ready-to-Use
Pre-coated transfection complexes on the NCP surface : plates can be stored @ -20 deg.

Applicable for High-Throughput screening
Friendly for automated operations and plate types (Up to 384 well plate)

Compare 2D and 3D functions
Easy to identify 3D specific phenotypes and biological functions

untreated (UT) negative control siRNA (Neg) cytotoxic siRNA (TOX)

Condition	Viability Counts (LU)
UT	80000
Neg	70000
TOX	10000

HeLa cell

On NanoCulture Plate, colony formation and efficient transfection had been observed 6 days after seeding


Contacts
SCIVAX USA, Inc.
<http://www.scivax.com/usa/>
100 TradeCenter, Suite G700, Woburn, MA 01801
TEL: (781) 569-5959 FAX: (781) 569-5201
E-mail: h-miura@scivax.com

CytoPathfinder, Inc.
<http://www.cytopathfinder.com/eng/>
0616 Bio-IT Research Building, AIST Tokyo Waterfront,
2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan
TEL: +81-3-5530-8086 FAX: +81-3-5530-8087
E-mail: tomohiro-yoshikawa@cytopathfinder.com

CytoPathfinder

Advantage over conventional method

Compound profiling; understanding complex cellular system



CytoPathfinder

Advantage over conventional method -Summary-

method	chemical			physical	biological
	Our STF	Liquid phase			
		forward	reverse		
reproducibility	high	low~medium	high(in case of automatic)	low	low~medium
Availability for hard to transfect cells	high (induced pluripotent stem cell,embryonic stem cell,hepatocyte, stem cell isolated from body tissue, primary cell, floating cell)	low~medium	low~medium	high(primary stem cells etc)	high
Transfection efficiency	same level as reverse method or higher	medium	Medium~high	high	high
Preparation of sample	Only add cells	complex	automation	Device needed	complex
Selection of optimization condition	Simple selection using optimization plates	Try and error	Try and error	Try and error	Try and error
Varied formats	Available max1,536well		Max density384 well	impossible	
Minimize number of cells	1,536 well, 500cells/well	384well, 3,000cells/well	384 well, 3,000cells/well	impossible	impossible
Double knockdown	available	impossible	impossible	difficult	difficult
storage	possible (12 months at-20°C)	impossible	impossible		
Scale of library	small~large	small	small~large (in case of automation)	small~large	small
others				Low viability of cells Damage of nucleic acid	Contamination, insertion mutation,inactivity by immunity

CytoPathfinder

Standard price of STF plate

FOB Japan price (US\$)

Nucleic acid	Kind of plate	Well format	Number of order	Unit price
siRNA/	Optimization	384	any number	290/1 plate
Plasmid DNA		96	any number	290/set 4plates
siRNA/	Customized*	1536/384/96	1	1,000/1plate
Plasmid DNA			2	670
			3~19	430
			20~49	380
			50~99	330
			100~	290

*siRNA/Plasmid DNA library is supplied from customer in case of customized plate production
 Above price is standard price level (FOB), Protocol of custom plate will vary according to your target cell, so fixed price will be estimated and negotiated including export package and air freight .

CytoPathfinder